- Bionano offers essential genomic information to a host of researchers and clinical customers, mapping genomic variations through its trademarked Saphyr system.
- Bionano benefits from strong sector tailwinds and equity inflows to the genomics sector where growth has outpaced the broader market in recent years.
- Management's growth forecasts are highly ambitious and investors must decide whether their risk profile allows an investment prior to evidence via annual sales growth.
For further details see:
Bionano Genomics: Weighing The Future Prospects Against The Here And Now